CN113262221A - 使用川地匹坦的治疗方法 - Google Patents

使用川地匹坦的治疗方法 Download PDF

Info

Publication number
CN113262221A
CN113262221A CN202110527432.8A CN202110527432A CN113262221A CN 113262221 A CN113262221 A CN 113262221A CN 202110527432 A CN202110527432 A CN 202110527432A CN 113262221 A CN113262221 A CN 113262221A
Authority
CN
China
Prior art keywords
sichuan
treatment
dipitant
disease
dapipristan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110527432.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·波利梅洛伯罗斯
L·W·利卡梅勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CN113262221A publication Critical patent/CN113262221A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202110527432.8A 2015-03-04 2016-03-04 使用川地匹坦的治疗方法 Pending CN113262221A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562128472P 2015-03-04 2015-03-04
US62/128,472 2015-03-04
US201562232644P 2015-09-25 2015-09-25
US62/232,644 2015-09-25
CN201680013797.6A CN107427502B (zh) 2015-03-04 2016-03-04 使用川地匹坦的治疗方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680013797.6A Division CN107427502B (zh) 2015-03-04 2016-03-04 使用川地匹坦的治疗方法

Publications (1)

Publication Number Publication Date
CN113262221A true CN113262221A (zh) 2021-08-17

Family

ID=55629110

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110527432.8A Pending CN113262221A (zh) 2015-03-04 2016-03-04 使用川地匹坦的治疗方法
CN201680013797.6A Active CN107427502B (zh) 2015-03-04 2016-03-04 使用川地匹坦的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680013797.6A Active CN107427502B (zh) 2015-03-04 2016-03-04 使用川地匹坦的治疗方法

Country Status (20)

Country Link
US (6) US10463655B2 (cg-RX-API-DMAC10.html)
EP (2) EP3265087B1 (cg-RX-API-DMAC10.html)
JP (4) JP6891385B2 (cg-RX-API-DMAC10.html)
KR (3) KR102860817B1 (cg-RX-API-DMAC10.html)
CN (2) CN113262221A (cg-RX-API-DMAC10.html)
AU (4) AU2016226006B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017018620A2 (cg-RX-API-DMAC10.html)
CA (2) CA3213864C (cg-RX-API-DMAC10.html)
CL (1) CL2017002238A1 (cg-RX-API-DMAC10.html)
DK (2) DK3265087T3 (cg-RX-API-DMAC10.html)
ES (1) ES2824552T3 (cg-RX-API-DMAC10.html)
FI (1) FI3730140T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20201627T1 (cg-RX-API-DMAC10.html)
HU (1) HUE050944T2 (cg-RX-API-DMAC10.html)
IL (1) IL254142B (cg-RX-API-DMAC10.html)
MX (2) MX385788B (cg-RX-API-DMAC10.html)
PT (2) PT3265087T (cg-RX-API-DMAC10.html)
RU (1) RU2770050C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016141341A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201706059B (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2770050C2 (ru) * 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
DK3710000T3 (da) * 2017-11-17 2025-06-16 Vanda Pharmaceuticals Inc Tradipitant til anvendelse til behandling af gastroparese
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
IL281569B2 (en) 2018-09-28 2025-04-01 Vanda Pharmaceuticals Inc Use of tradipient in motion sickness
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
KR20220145844A (ko) 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239786A1 (en) * 2002-04-26 2005-10-27 Eli Lilly Company Triazole derivatives as tachykinin receptor antagonists
CN1863791A (zh) * 2003-10-24 2006-11-15 伊莱利利公司 {2-[1-(3,5-双-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]-吡啶-3-基}-(2-氯苯基)-甲酮的新晶形
WO2014209962A1 (en) * 2013-06-24 2014-12-31 Tigercat Pharma, Inc. Use of nk-1 receptor antagonist serlopitant in pruritus

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305718D0 (en) 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
TW263498B (cg-RX-API-DMAC10.html) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
GB9513972D0 (en) 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
SI1501808T1 (sl) * 2002-04-26 2008-10-31 Lilly Co Eli Antagonisti tahikininskega receptorja
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Th1型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
WO2007096782A2 (en) 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compositions for disorders associated wtth metachromatic cell activation
EP2121610B1 (en) 2006-12-20 2014-04-02 Eli Lilly & Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
EP2464230B1 (en) 2009-08-14 2016-10-05 OPKO Health, Inc. Intravenous formulations of rolapitant
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
PE20121483A1 (es) 2009-11-18 2012-12-02 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados
EP2931253A1 (en) 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
US8906951B1 (en) * 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
RU2770050C2 (ru) * 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
WO2016195723A1 (en) 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017093857A1 (en) 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions
EA201891472A1 (ru) 2015-12-22 2018-12-28 Такеда Фармасьютикал Компани Лимитед Тройные модуляторы эндосомальных рецепторов, сопряженных с g-белком
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
DK3710000T3 (da) * 2017-11-17 2025-06-16 Vanda Pharmaceuticals Inc Tradipitant til anvendelse til behandling af gastroparese
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
IL281569B2 (en) 2018-09-28 2025-04-01 Vanda Pharmaceuticals Inc Use of tradipient in motion sickness
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239786A1 (en) * 2002-04-26 2005-10-27 Eli Lilly Company Triazole derivatives as tachykinin receptor antagonists
CN1863791A (zh) * 2003-10-24 2006-11-15 伊莱利利公司 {2-[1-(3,5-双-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]-吡啶-3-基}-(2-氯苯基)-甲酮的新晶形
WO2014209962A1 (en) * 2013-06-24 2014-12-31 Tigercat Pharma, Inc. Use of nk-1 receptor antagonist serlopitant in pruritus

Also Published As

Publication number Publication date
EP3730140A1 (en) 2020-10-28
MX2021010460A (es) 2021-09-21
AU2021202956A1 (en) 2021-06-03
HK1248552A1 (zh) 2018-10-19
CL2017002238A1 (es) 2018-04-20
FI3730140T3 (fi) 2026-07-14
EP3730140B1 (en) 2026-05-06
IL254142A0 (en) 2017-10-31
US10463655B2 (en) 2019-11-05
RU2017134443A (ru) 2019-04-04
CN107427502B (zh) 2021-06-04
MX2017011279A (es) 2018-01-25
US11324735B2 (en) 2022-05-10
AU2021202956B2 (en) 2023-06-29
WO2016141341A1 (en) 2016-09-09
CA3213864C (en) 2026-02-03
CA3213864A1 (en) 2016-09-09
AU2025210905A1 (en) 2025-08-21
US20200360358A1 (en) 2020-11-19
HRP20201627T1 (hr) 2021-02-19
PT3265087T (pt) 2020-10-15
RU2017134443A3 (cg-RX-API-DMAC10.html) 2019-09-05
MX385788B (es) 2025-03-18
US10772880B2 (en) 2020-09-15
JP2023052486A (ja) 2023-04-11
US20190290626A1 (en) 2019-09-26
KR20230173743A (ko) 2023-12-27
JP2018507243A (ja) 2018-03-15
NZ735121A (en) 2024-07-26
DK3730140T3 (da) 2026-07-27
AU2023233141B2 (en) 2025-05-22
US20250205213A1 (en) 2025-06-26
KR20170122777A (ko) 2017-11-06
CA2978736A1 (en) 2016-09-09
ZA201706059B (en) 2023-08-30
KR20250136946A (ko) 2025-09-16
KR102860817B1 (ko) 2025-09-16
DK3265087T3 (da) 2020-10-19
HUE050944T2 (hu) 2021-01-28
US20180110761A1 (en) 2018-04-26
ES2824552T3 (es) 2021-05-12
RU2770050C2 (ru) 2022-04-14
US20220226295A1 (en) 2022-07-21
JP2024074963A (ja) 2024-05-31
PT3730140T (pt) 2026-07-16
AU2016226006A1 (en) 2017-09-21
BR112017018620A2 (pt) 2018-04-17
US12318375B2 (en) 2025-06-03
JP2021073258A (ja) 2021-05-13
CA2978736C (en) 2023-11-07
EP3265087B1 (en) 2020-07-22
AU2023233141A1 (en) 2023-10-12
AU2016226006B2 (en) 2021-03-04
US20190290625A1 (en) 2019-09-26
JP6891385B2 (ja) 2021-06-18
CN107427502A (zh) 2017-12-01
EP3265087A1 (en) 2018-01-10
IL254142B (en) 2022-05-01

Similar Documents

Publication Publication Date Title
CN107427502B (zh) 使用川地匹坦的治疗方法
AU2014249530B2 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
US20240390353A1 (en) Method of treatment with tradipitant
RU2810253C2 (ru) Способ лечения с применением традипитанта
HK1248552B (en) Method of treatment with tradipitant
JP2007246507A (ja) 疲労の予防・治療組成物及び予防・治療方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination